Budesolv is an innovative aqueous budesonide formulation based on Marinosolv® drug delivery platform, which has the potential to dramatically improve the solubility and bioavailability of poorly water-soluble compounds. This leads to faster therapeutic onset and effective treatment at significantly lower doses.
The technology is broadly applicable across a wide range of drug classes, making it a versatile foundation for next-generation formulations.
Strong symptom relief after the first dose
Patient-friendly low dose, suitable for pediatric use
Preservative-free formulation for safe, long-term treatment (of chronic conditions)
Sterile formulation for enhanced safety
Budesolv has successfully completed a Phase III clinical trial.
We are actively seeking strategic partners for local and regional licensing and commercialization.
With its innovative formulation and strong clinical data, Budesolv presents a unique opportunity for companies aiming to strengthen their position and establish a market-leading role—in the allergic rhinitis segment.
